Insulin degludec

CAS No. 844439-96-9

Insulin degludec ( —— )

Catalog No. M25046 CAS No. 844439-96-9

Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by type 1 and type 2 dabetes. Insulin degludec shows binding efficiency with an IC50 value of 19.59 nM/L for insulin receptor. Insulin degludec can be used for the research of type 1 and type 2 diabetes.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 298 In Stock
10MG 496 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Insulin degludec
  • Note
    Research use only, not for human use.
  • Brief Description
    Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by type 1 and type 2 dabetes. Insulin degludec shows binding efficiency with an IC50 value of 19.59 nM/L for insulin receptor. Insulin degludec can be used for the research of type 1 and type 2 diabetes.
  • Description
    Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by type 1 and type 2 dabetes. Insulin degludec shows binding efficiency with an IC50 value of 19.59 nM/L for insulin receptor. Insulin degludec can be used for the research of type 1 and type 2 diabetes.Insulin degludec (0.001-1000 nM; 12 h) binds with insulin receptor with an IC50 value of 19.59 nM/L.Insulin degludec (200 nM; 10 min) increases glucose uptake in HL-1 cells.
  • Synonyms
    ——
  • Pathway
    Tyrosine Kinase
  • Target
    Insulin Receptor
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    844439-96-9
  • Formula Weight
    ——
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    0.1 M HCL : 50 mg/mL (ultrasonic and adjust pH to 2 with 0.1 M HCL)
  • SMILES
    N/A
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Bataglini C, et al. Insulin degludec and glutamine dipeptide modify glucose homeostasis and liver metabolism in diabetic mice undergoing insulin-induced hypoglycemia. J Appl Biomed. 2021 Dec;19(4):210-219. 2. Hartmann T, et al. Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function. Cardiovasc Diabetol. 2016 Jul
molnova catalog
related products
  • [D-Ala2]-GIP (human)

    Highly potent GIP receptor agonist (EC50 = 630 ± 119 pM). Displays equivalent cAMP stimulating properties and improved resistance to enzymatic degradation compared to native GIP in cells expressing wild type GIP receptor. Improves glucose tolerance, insulin release and cognitive function in various animal models of obesity and diabetes. Displays neuroprotective effects in an MPTP model of PD.

  • Insulin degludec

    Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by type 1 and type 2 dabetes. Insulin degludec shows binding efficiency with an IC50 value of 19.59 nM/L for insulin receptor. Insulin degludec can be used for the research of type 1 and type 2 diabetes.

  • MSDC-0160

    A new generation insulin sensitizer and mitochondrial target of thiazolidinediones (mTOT) modulator that has low affinity for binding and activation of PPARγ (EC50=23.7 uM).